COX-2 function has been the target of pharmaceutical intervention in a multitude of widespread degenerating conditions, including autoimmune diseases, gastric inflammation, and several different cancers, such as colon, gastric, breast, and lung cancer ( Koehne and Dubois, 2004;  Xu et al., 2004;  Wallace, 2005;  Wang et al., 2005;  Diaz-Cruz and Brueggemeier, 2006;  Krysan et al., 2006). This evidence concerns the gene PTGS2 and cancer.